GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Purchased by Ballentine Partners LLC

Ballentine Partners LLC lifted its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 8.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 7,189 shares of the company’s stock after purchasing an additional 559 shares during the quarter. Ballentine Partners LLC’s holdings in GE HealthCare Technologies were worth $675,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Capital Research Global Investors increased its holdings in shares of GE HealthCare Technologies by 5.2% in the first quarter. Capital Research Global Investors now owns 53,991,923 shares of the company’s stock valued at $4,908,406,000 after purchasing an additional 2,647,204 shares during the last quarter. Vanguard Group Inc. grew its position in GE HealthCare Technologies by 9.2% in the first quarter. Vanguard Group Inc. now owns 48,519,340 shares of the company’s stock worth $4,410,893,000 after acquiring an additional 4,107,746 shares during the period. The Manufacturers Life Insurance Company grew its position in GE HealthCare Technologies by 18.0% in the second quarter. The Manufacturers Life Insurance Company now owns 1,245,961 shares of the company’s stock worth $97,088,000 after acquiring an additional 189,956 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its position in GE HealthCare Technologies by 2.1% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,025,320 shares of the company’s stock worth $93,212,000 after acquiring an additional 20,776 shares during the period. Finally, Stonegate Investment Group LLC grew its position in GE HealthCare Technologies by 1.0% in the third quarter. Stonegate Investment Group LLC now owns 979,649 shares of the company’s stock worth $91,940,000 after acquiring an additional 9,572 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Buying and Selling at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Thomas J. Westrick sold 2,750 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $80.78, for a total value of $222,145.00. Following the sale, the chief executive officer now directly owns 17,509 shares in the company, valued at $1,414,377.02. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.27% of the stock is owned by insiders.

GE HealthCare Technologies Trading Down 0.5 %

NASDAQ:GEHC opened at $88.42 on Friday. The firm has a market cap of $40.38 billion, a PE ratio of 25.70, a price-to-earnings-growth ratio of 3.34 and a beta of 1.18. The stock has a fifty day moving average price of $88.42 and a 200 day moving average price of $83.43. GE HealthCare Technologies Inc. has a 12-month low of $62.35 and a 12-month high of $94.55. The company has a current ratio of 1.06, a quick ratio of 0.82 and a debt-to-equity ratio of 1.05.

GE HealthCare Technologies (NASDAQ:GEHC) last released its earnings results on Wednesday, July 31st. The company reported $1.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.02. The firm had revenue of $4.84 billion during the quarter, compared to analyst estimates of $4.88 billion. GE HealthCare Technologies had a return on equity of 25.26% and a net margin of 8.10%. GE HealthCare Technologies’s revenue was up .5% compared to the same quarter last year. During the same period last year, the business posted $0.92 earnings per share. Sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.26 earnings per share for the current fiscal year.

GE HealthCare Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Friday, October 18th will be issued a $0.03 dividend. The ex-dividend date of this dividend is Friday, October 18th. This represents a $0.12 dividend on an annualized basis and a yield of 0.14%. GE HealthCare Technologies’s dividend payout ratio (DPR) is presently 3.49%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. BTIG Research upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Wednesday, September 18th. Redburn Atlantic upgraded GE HealthCare Technologies to a “strong-buy” rating in a research report on Thursday, August 1st. Stifel Nicolaus increased their price objective on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. JPMorgan Chase & Co. assumed coverage on GE HealthCare Technologies in a research report on Monday, September 9th. They issued a “neutral” rating and a $90.00 price objective for the company. Finally, Evercore ISI increased their price objective on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $94.23.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.